Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 12/20 | 0.39 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.38 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12626973 | 0.87 | USP2 (0.46) | USP2SMN1; SMN2RECQLGPR119HCRTR1 | |
| SCHEMBL12626975 | 0.86 | USP2 (0.44) | USP2SMN1; SMN2RECQLGPR119HCRTR1 | |
| SCHEMBL15426422 | 0.80 | HCRTR1 (0.51) | GPR119HCRTR1HCRTR2 | |
| SCHEMBL12627185 | 0.79 | HCRTR1 (0.50) | HCRTR1HCRTR2 | |
| SCHEMBL12655883 | 0.79 | HCRTR1 (0.50) | GPR119HCRTR1HCRTR2 | |
| SCHEMBL12656193 | 0.78 | L3MBTL1 (0.57) | GPR119HCRTR1HCRTR2 | |
| SCHEMBL15426424 | 0.78 | HCRTR1 (0.48) | HCRTR1HCRTR2 | |
| SCHEMBL12623931 | 0.78 | HCRTR1 (0.48) | GPR119HCRTR1HCRTR2 | |
| SCHEMBL12627108 | 0.78 | HCRTR1 (0.48) | GPR119HCRTR1HCRTR2 | |
| SCHEMBL22368464 | 0.75 | HCRTR1 (0.38) | USP2SMN1; SMN2GPR119HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2918587-B1 | Filamin A binding compounds and their use as anti-inflammatory and analgesic agents | PAIN THERAPEUTICS INC (US) | 2018-04-04 | — | — | EP | disclosed |
| EP-2488177-B1 | FILAMIN A BINDING ANTI-INFLAMMATORY AND ANALGESIC | PAIN THERAPEUTICS INC (US) | 2016-10-12 | — | — | EP | disclosed |
| US-20160251374-A1 | FILAMIN A BINDING ANTI-INFLAMMATORY AND ANALGESIC | BURNS BARBIER LINDSAY (US) | 2016-09-01 | — | — | US | disclosed |
| US-20160251374-A1 | FILAMIN A BINDING ANTI-INFLAMMATORY AND ANALGESIC | BURNS BARBIER LINDSAY (US) | 2016-09-01 | — | — | US | disclosed |
| US-9340558-B2 | Filamin a binding anti-inflammatory and analgesic | PAIN THERAPEUTICS INC. (US) | 2016-05-17 | — | — | US | disclosed |
| US-9340558-B2 | Filamin a binding anti-inflammatory and analgesic | PAIN THERAPEUTICS INC. (US) | 2016-05-17 | — | — | US | disclosed |
| EP-2918587-A2 | Filamin a binding anti-inflammatory and analgesic | Pain Therapeutics, Inc. (US) | 2015-09-16 | — | — | EP | disclosed |
| US-20140113895-A1 | FILAMIN A BINDING ANTI-INFLAMMATORY AND ANALGESIC | PAIN THERAPEUTICS, INC. | 2014-04-24 | — | — | US | disclosed |
| US-8653068-B2 | Filamin A binding anti-inflammatory and analgesic | PAIN THERAPEUTICS, INC. (US) | 2014-02-18 | — | — | US | disclosed |
| US-8653068-B2 | Filamin A binding anti-inflammatory and analgesic | PAIN THERAPEUTICS, INC. (US) | 2014-02-18 | — | — | US | disclosed |
| US-20110105487-A1 | FILAMIN A BINDING ANTI-INFLAMMATORY AND ANALGESIC | PAIN THERAPEUTICS | 2011-05-05 | — | — | US | disclosed |
| US-20110105487-A1 | FILAMIN A BINDING ANTI-INFLAMMATORY AND ANALGESIC | PAIN THERAPEUTICS | 2011-05-05 | — | — | US | disclosed |
| US-20110105481-A1 | FILAMIN A BINDING ANTI-INFLAMMATORY AND ANALGESIC | PAIN THERAPEUTICS | 2011-05-05 | — | — | US | disclosed |
| US-20110105481-A1 | FILAMIN A BINDING ANTI-INFLAMMATORY AND ANALGESIC | PAIN THERAPEUTICS | 2011-05-05 | — | — | US | disclosed |
| WO-2010051497-A1 | FILAMIN A BINDING ANTI-INFLAMMATORY AND ANALGESIC | PAIN THERAPEUTICS, INC. (US) | 2010-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160251374-A1 | FILAMIN A BINDING ANTI-INFLAMMATORY AND ANALGESIC | FLNA, FLNB, OPRK1 | USP2 4870/4885SMN1; SMN2 2583/4885RECQL 1271/4885 |
| US-20110105487-A1 | FILAMIN A BINDING ANTI-INFLAMMATORY AND ANALGESIC | FLNA, FLNB, FPR1 | USP2 4860/4885SMN1; SMN2 2503/4885RECQL 1541/4885 |
| US-20110105481-A1 | FILAMIN A BINDING ANTI-INFLAMMATORY AND ANALGESIC | FLNA, FLNB, OPRK1 | USP2 4870/4885SMN1; SMN2 2583/4885RECQL 1271/4885 |
| US-20140113895-A1 | FILAMIN A BINDING ANTI-INFLAMMATORY AND ANALGESIC | FLNA, FLNB, OPRK1 | USP2 4870/4885SMN1; SMN2 2583/4885RECQL 1271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.